Patient mutations alter ATRX targeting to PML nuclear bodies.
about
An Adenovirus DNA Replication Factor, but Not Incoming Genome Complexes, Targets PML Nuclear Bodies.Kaposi's sarcoma-associated herpesvirus K-Rta exhibits SUMO-targeting ubiquitin ligase (STUbL) like activity and is essential for viral reactivationLoss of Atrx sensitizes cells to DNA damaging agents through p53-mediated death pathwaysPost-Translational Modifications of Kaposi's Sarcoma-Associated Herpesvirus Regulatory Proteins - SUMO and KSHVATRX induction by mutant huntingtin via Cdx2 modulates heterochromatin condensation and pathology in Huntington's disease.Single-cell analysis of Daxx and ATRX-dependent transcriptional repressionAtrx deficiency induces telomere dysfunction, endocrine defects, and reduced life span.Histone turnover and chromatin accessibility: Critical mediators of neurological development, plasticity, and disease.New insights into the role of PML in tumour suppression.The XNP remodeler targets dynamic chromatin in Drosophila.The role of PML in the nervous system.The PML-Interacting Protein DAXX: Histone Loading Gets into the Picture.Emerging roles of ATRX in cancer.Control of human adenovirus type 5 gene expression by cellular Daxx/ATRX chromatin-associated complexes.The ATRX cDNA is prone to bacterial IS10 element insertions that alter its structure.Human cytomegalovirus protein pp71 displaces the chromatin-associated factor ATRX from nuclear domain 10 at early stages of infection.Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition.ATRX is a regulator of therapy induced senescence in human cells.XNP/dATRX interacts with DREF in the chromatin to regulate gene expression.Loss of ATRX leads to chromosome cohesion and congression defects.Retinal interneuron survival requires non-cell-autonomous Atrx activity.ATRX in chromatin assembly and genome architecture during development and disease.Mutant ATRX: uncovering a new therapeutic target for glioma.
P2860
Q27320996-C6EDF035-4035-419C-87F6-54EC378BD530Q28535568-44B9DB13-BA63-4FC8-9EF3-0273349B7E58Q34533223-A35DF2A7-B501-4F99-BD58-6F78E86792C5Q35755464-1CE5C057-DC30-4CD7-86FB-FA653460AA28Q36028454-B53F8D53-A7DD-480D-AA36-ABD9F49D0A19Q36580532-6AFD129F-D36E-4DAB-9BAD-B10A1882C2BDQ36793436-DED03EF0-90A4-4634-BE04-87E308CFE4E3Q37143027-2F8123F4-08D2-44B2-82AA-51A781F7E63AQ37173760-6701503B-4892-4C49-A306-9BB476941133Q37300498-C121098B-4F2C-434F-AAE3-99A9D8B65A77Q37821367-CDE838D0-BAAD-4774-92CE-A17A946D0475Q38113966-CB406686-A8CB-4DA9-A5B2-BF55339E1540Q38662646-47B4C19F-C5AF-498E-9209-049EB8916F74Q39196984-491DC761-91A5-4953-ABB3-977A76C510DCQ39614095-95FCA12C-2765-420E-860D-E6674E2EE0C1Q39929078-68E93FD4-2D68-4D45-BAD1-10315EC44B44Q41439061-8FBDC502-430E-435C-AF30-F8B9D278861CQ41565938-4C0962B6-433F-4386-8F8D-E2CE0904DD8DQ41577913-8C0CECE7-F90A-49C0-8703-07BAD6A9A6E8Q41825660-1D57E9DC-1165-4CEA-98C2-CD3E651CDBFDQ47806032-DA58DA0E-2CC6-4513-9A32-182E4FB8C56CQ50790126-8E533034-2457-4A5B-9A68-AB6E2F5A6238Q55456861-696FE462-9D1C-4956-AF92-B42884610804
P2860
Patient mutations alter ATRX targeting to PML nuclear bodies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Patient mutations alter ATRX targeting to PML nuclear bodies.
@en
Patient mutations alter ATRX targeting to PML nuclear bodies.
@nl
type
label
Patient mutations alter ATRX targeting to PML nuclear bodies.
@en
Patient mutations alter ATRX targeting to PML nuclear bodies.
@nl
prefLabel
Patient mutations alter ATRX targeting to PML nuclear bodies.
@en
Patient mutations alter ATRX targeting to PML nuclear bodies.
@nl
P2093
P2860
P356
P1476
Patient mutations alter ATRX targeting to PML nuclear bodies.
@en
P2093
Chantal F Medina
David J Picketts
Jasmine Healy
Magdalena Jagla
Nathalie G Bérubé
Todd Hodgson
P2860
P2888
P304
P356
10.1038/SJ.EJHG.5201943
P577
2007-10-24T00:00:00Z